# NCT03579771 (NCT03579771)

> Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

No report yet. It can be ordered.

- Drugs tested: gemcitabine plus cisplatin plus nab-paclitaxel
- Indication: resectable high-risk intrahepatic cholangiocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03579771
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Emory University
- Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions: Cisplatin; Gemcitabine; Nab-paclitaxel
- Enrollment: 30
- Primary outcome: Number of Participants Who Completed All Preoperative and Operative Therapy
- Primary outcome: Number of Participants With Adverse Events

## Indexed commentary on NCT03579771 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03579771